Resource overview
Developing Chimeric Antigen Receptor (CAR) constructs for CAR-T cell therapy is challenged by antigen specificity, which can lead to resistance, off-tumor effects, and toxicities. Advanced optical biosensing, particularly Biolayer Interferometry (BLI), helps overcome these issues by enabling real-time, label-free analysis of biomolecular interactions. BLI provides insights into binding kinetics, affinity, and concentrations with minimal preparation and low sample volumes, making it well-suited for high-throughput CAR-T research. This article highlights studies using the Octet® BLI system to optimize CAR constructs and advance strategies for improving specificity, safety, and efficacy in CAR-T therapies.
Key takeaways:
- Challenges in CAR development
- Strategies for fine-tuning specificity to minimize side effects
- Tips for addressing high and low antigen densities
- Approaches for targeting solid tumors with low antigen density
- Innovative methods to improve CAR-T therapies
Resource details:
- Document type: Article
- Page count: 8
- Read time: 12 minutes
- Last updated: September 2024